LabCorp announces availability of xTAG CYP2D6 genotype assay LabCorp (LH) announced the availability of the xTAG CYP2D6 Kit v3 from Luminex (LMNX). The xTAG CYP2D6 Kit v3 is an FDA cleared qualitative genotyping assay that aids clinicians in determining strategies for therapeutics metabolized by the CYP2D6 gene product.
Quest Diagnostics downgraded to Underperform from Market Perform at Wells Fargo Wells Fargo downgraded Quest Diagnostics (DGX) to its sell-equivalent Underperform rating saying the charges associated with the company's Invigorate savings initiative should not be viewed as one-time by investors. Wells thinks the initiative will need to be ongoing as Quest's margins are declining. It keeps a $60-$65 price target range for shares. The diagnostic testing company closed yesterday up 52c to $71.09. Quest’s main competitor is LabCorp (LH).
Charles River Labs upgraded to Outperform from Market Perform at William Blair William Blair upgraded Charles River Labs (CRL) to Outperform citing improving demand for early-stage development services as well as opportunity for share gains due to Covance’s (CVD) pending merger with LabCorp (LH).